PDL BioPharma (PDL) has announced that following the completion of a strategic review process it has decided to cease additional strategic investments and monetize the company’s assets, returning net proceeds to shareholders. As the assets are not focused on any one area within healthcare, we believe they will likely need to be sold off piecemeal, which will lead to a relatively lengthy process (the company has estimated two to three years or longer). PDL’s stock has typically tra
01 Apr 2020
PDL BioPharma - Company to seek to monetize assets
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
PDL BioPharma - Company to seek to monetize assets
- Published:
01 Apr 2020 -
Author:
Maxim Jacobs -
Pages:
6
PDL BioPharma (PDL) has announced that following the completion of a strategic review process it has decided to cease additional strategic investments and monetize the company’s assets, returning net proceeds to shareholders. As the assets are not focused on any one area within healthcare, we believe they will likely need to be sold off piecemeal, which will lead to a relatively lengthy process (the company has estimated two to three years or longer). PDL’s stock has typically tra